1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Ascendis Phase III Data Gives TransCon PTH An Edge In Hypoparathyroidism

 
• By Jessica Merrill

The firm plans to submit to the US FDA in the third quarter and with the European Medicines Agency in the fourth quarter based on positive Phase III study results.

Soccer Goal
A Phase III trial for Ascendis' drug was positive • Source: Alamy

More than three-quarters of patients with hypoparathyroidism (HP) treated with Ascendis Pharma A/S’s TransCon PTH in a Phase III trial were able to stop taking conventional therapy, a potential point of differentiation in the market.

The company announced on 13 March that a Phase III trial testing TransCon PTH in HP patients met its primary endpoint, positioning Ascendis to bring a second commercial drug to market. The Danish company's first drug, approved in the US in 2021 and in Europe in January, is Skytrofa (lonapegsomatropin-tcgd) for growth hormone deficiency

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.